Casey Woodring

would be curious to hear how much that forensic TSA 1-timer you called out was in the quarter. Was that baked into the guide

Can you just talk about what LC/MS grew in the quarter and walk through the growth phasing for LC and LC/MS over the course of the year?

Can you maybe just elaborate on what the financial impact could look like from those contracts

within pharma in the quarter, excluding the CDMO, could you break down large molecule versus small molecule growth?

you talked about maintaining dry powder for M&A. How should we think about that in relation to some of the comments

Can you just elaborate on that and if that's expected to be a drag on DSA margins next year?

Can you just elaborate on what's driving that? What sort of margin differential in the work that's getting canceled looks like?

on the forward outlook, how should we think about potential headwinds here for large pharma demand?

what your updated expectations are for biotech and DSA this year, just given the weaker funding numbers to start the year?

any quick thoughts on how something like that would impact pharma budgets and that customer group's preclinical drug development spending

maybe can you just walk through what exactly is offsetting that lower respiratory number for the year?

can you just give us any sense of what orders grew sequentially in 4Q or what book-to-bill was in the quarter?

at what point you'll run into the law of large numbers there. And ultimately, where do you think diagnostics growth will shake out relative to that mid-single-digit range

it's pretty insulated from a lot of this macro noise. So curious how that's contributing to that molecular growth rate moving forward?

I'm just curious on that 12% non-product revenue growth rate, you called out mainly on the breast service component. How did that compare to your expectations in the quarter?

can you break out performance in the quarter between US and international customers?

the potential margin benefit once the consolidation is finished and the next gantry is launched and ramped?

I was curious if you could break out the 1Q guide by business segment

if there's anything baked in there from a supply chain perspective that 19.5% tax rate for '25

Is the March change in Harmonized Tariff Schedule codes included in that?

the sort of strategy shift towards focusing on the midrange market there that's really driving growth. So just curious if that's a tailwind that you're assuming extends into 2026

Just what's the latest there on the ground in terms of potential stimulus and what that could mean for 2026

maybe just parse out drivers by segment and the outlook in that region for the back half of the year

just curious on timing of when you would expect some of these CapEx announcements to eventually flow through into orders and revenue for you guys

maybe just walk through where the softness occurred in the quarter. I think we've seen a couple of reports of a weaker microbiology market in China

curious if you'd expect China to return to growth at any point this year?

what's assumed for US academic and government growth in 2026

Curious on how the performance played out relative to your expectations in the quarter

Curious if you could just unpack that for us. How much of that was price? How much was new product contribution in bioseparations

TA. You said that business came back faster than expected. I think you had previously assumed TA would be down 5% in the second half